

Citations

1. Geis LS, Smith DG, Smith FL et al. Tyrosine influence on amphetamine self-administration and brain catecholamines in the rat. *Pharmacol Biochem Behav* 1986;25:1027-1033.
2. Woods SK, Meyer JS. Exogenous tyrosine potentiates the methylphenidate-induced increase in extracellular dopamine in the nucleus accumbens: a microdialysis study. *Brain Res* 1991;560:97-105.
3. McTavish SF, McPherson MH, Sharp T, Cowen PJ. Attenuation of some subjective effects of amphetamine following tyrosine depletion. *J Psychopharmacol* 1999;13:144-147.
4. Gold MS, Pottash AC, Annitto WJ et al. Cocaine withdrawal: efficacy of tyrosine. *Soc Neurosci Abstr* 1983;9:157.
5. Chadwick MJ, Gregory DL, Wendling G. A double-blind amino acids, l-tryptophan and l-tyrosine, and placebo study with cocaine-dependent subjects in an inpatient chemical dependency treatment center. *Am J Drug Alcohol Abuse* 1990;16:275-286.
6. Tutton CS, Crayton JW. Current pharmacotherapies for cocaine abuse: a review. *J Addict Dis* 1993;12:109-127.
7. Galloway GP, Frederick SL, Thomas S et al. A historically controlled trial of tyrosine for cocaine dependence. *J Psychoactive Drugs* 1996;28:305-309.
8. Rosecan JS. The treatment of cocaine abuse with imipramine, l-tyrosine, and l-tryptophan: an open trial with 25 patients. *The VII World Congress of Psychiatry*. Vienna; 1983.
9. Verebey K, Gold MS. Psychopharmacology of cocaine: behavior neurophysiology, neurochemistry and proposed treatment. In: Morgan DW, ed. *Psychopharmacology: Impact on Clinical Psychiatry*. St Louis, Tokyo: Ishiyaku EuroAmerica; 1985:219-241.
10. Awad AG. Diet and drug interactions in the treatment of mental illness: a review. *Can J Psychiatry* 1984;29:609-613.
11. Riederer P. l-Dopa competes with tyrosine and tryptophan for human brain uptake. *Nutr Metab* 1980;24:417-423.
12. Growdon JH, Melamed E, Logue M et al. Effects of oral l-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. *Life Sci* 1982;30:827-832.
13. Lemoine P, Robelin N, Sebert P, Mouret J. [l-Tyrosine: a long term treatment of Parkinson's disease]. *C R Acad Sci III* 1989;309:43-47.
14. McGrath PJ, Stewart JW, Quitkin FM. A possible l-deprenyl induced hypertensive reaction. *J Clin Psychopharmacol* 1989;9:310-311.
15. Raisfeld IH. Cardiovascular complications of antidepressant therapy: interactions at the adrenergic neuron. *Am Heart J* 1972;83:129-133.
16. Levy AB, Bucher P, Votolato N. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment. *Can J Psychiatry* 1985;30:434-436.
17. Goff DC. Two cases of hypomania following the addition of l-tryptophan to a monoamine oxidase inhibitor. *Am J Psychiatry* 1985;142:1487-1488.
18. Alvine G, Black DW, Tsuang D. Case of delirium secondary to phenelzine/l-tryptophan combination. *J Clin Psychiatry* 1990;51:311.
19. Moller SE. Effect of oral contraceptives on tryptophan and tyrosine availability: evidence for a possible contribution to mental depression. *Neuropsychobiology* 1981;7:192-200.
20. Moller SE, Maach-Moller B, Olesen M et al. Tyrosine metabolism in users of oral contraceptives. *Life Sci* 1995;56:687-695.
21. Moller SE, Moller BM, Olesen M, Fjalland B. Effects of oral contraceptives on plasma neutral amino acids and cholesterol during a menstrual cycle. *Eur J Clin Pharmacol* 1996;50:179-184.
22. Hull KM, Maher TJ. l-Tyrosine fails to potentiate several peripheral actions of the sympathomimetics. *Pharmacol Biochem Behav* 1991;39:755-759.
23. Hull KM, Maher TJ. Effects of l-tyrosine on mixed-acting sympathomimetic-induced pressor actions. *Pharmacol Biochem Behav* 1992;43:1047-1052.
24. Hull KM, Tolland DE, Maher TJ. l-Tyrosine potentiation of opioid-induced analgesia utilizing the hot-plate test. *J Pharmacol Exp Ther* 1994;269:1190-1195.
25. Ali BH. The effect of l-tyrosine on some anti-nociceptive and non-nociceptive actions of morphine in mice. *Gen Pharmacol* 1995;26:407-409.
26. Gelenberg AJ, Gibson CJ, Wojcik JD. Neurotransmitter precursors for the treatment of depression. *Psychopharmacol Bull* 1982;18:7-18.
27. Gelenberg AJ, Gibson CJ. Tyrosine for the treatment of depression. *Nutr Health* 1984;3:163-173.
28. Van Praag HM. In search of the mode of action of antidepressants: 5-HTP/tyrosine mixtures in depression. *Adv Biochem Psychopharmacol* 1984;39:301-314.
29. Meyers S. Use of neurotransmitter precursors for treatment of depression. *Altern Med Rev* 2000;5:64-71.
30. Gelenberg AJ, Wojcik JD, Falk WE et al. Tyrosine for depression: a double-blind trial. *J Affect Disord* 1990;19:125-132.

Reference Literature

- Alvestrand A, Ahlberg M, Forst P, et al. Clinical results of long-term treatment with a low protein diet and a new amino acid preparation in patients with chronic uremia. *Clin Nephrol* 1983;19(2):67-73.
- Awad AG. Diet and drug interactions in the treatment of mental illness: a review. *Can J Psychiatry* 1984;29:609-613. (Review)
- Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. *Brain Res Bull* 1989;22(4):759-762.
- Belin MF, Chouvet G, Pujol JF. [Synaptosomal transport of cerebral tryptophan and tyrosine: stimulation of the rate of uptake after administration of reserpine or monoamine oxidases inhibitor.] *Biochem Pharmacol* 1974;23(3):587-597. [French]
- Blum K, Wallace JE. Effects of catecholamine synthesis inhibition on ethanol-induced withdrawal symptoms in mice. *Br J Pharmacol* 1974;51(1):109-111.
- Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. *Arch Dermatol* 1999;135:216-217.
- Chakraborty DP, Roy S, Chakraborty AK. Vitiligo, psoralen, and melanogenesis: some observations and understanding. *Pigment Cell Res* 1996;9(3):107-116.
- Chiaroni P, Azorin JM, Bovier P, et al. A multivariate analysis of red blood cell membrane transports and plasma levels of L-tyrosine and L-tryptophan in depressed patients before treatment and after clinical improvement. *Neuropsychobiology* 1990;23(1):1-7.
- Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. *Brain Res Bull* 1994;33(3):319-323.
- Deijen JB, Wientjes CJ, Vullings HF, et al. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. *Brain Res Bull* 1999;48:203-209.
- Dollins AB, Krock LP, Storm WF, et al. L-tyrosine ameliorates some effects of lower body negative pressure stress. *Physiol Behav* 1995;57:223-230.
- Dyck LE. Effect of decarboxylase inhibitors on brain p-tyrosine levels. *Biochem Pharmacol* 1987;36(8):1373-1376.
- Dyck LE, Dewar KM. Inhibition of aromatic L-amino acid decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine. *J Neurochem* 1986;46(6):1899-1903.
- Elwes RD, Crewes H, Chesterman LP, et al. Treatment of narcolepsy with L-tyrosine: double-blind, placebo-controlled trial. *Lancet* 1989;2(8671):1067-1069.
- Fernstrom JD. Can nutrient supplements modify brain function? *Am J Clin Nutr* 2000;71(6 Suppl):1669S-1675S.
- Fugh-Berman A, Cott JM. Dietary supplements and natural products as psychotherapeutic agents. *Psychosom Med* 1999;61:712-728. (Review)
- Galloway GP, Frederick SL, Thomas S, et al. A historically controlled trial of tyrosine for cocaine dependence. *J Psychoactive Drugs* 1996;28(3):305-309.
- Geha RM, Rebrin I, Chen K, et al. Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. *J Biol Chem* 2001;276(13):9877-9882.
- Gelenberg AJ, Gibson CJ. Tyrosine for the treatment of depression. *Nutr Health* 1984;3:163-173.
- Gelenberg AJ, Gibson CJ, Wojcik JD. Neurotransmitter precursors for the treatment of depression. *Psychopharmacol Bull* 1982;18(1):7-18. (Review)
- Gelenberg AJ, Wojcik JD, Falk WE, et al. Tyrosine for depression: a double-blind trial. *J Affect Disord* 1990;19:125-132.
- Gelenberg AJ, Wojcik JD, Gibson CJ, et al. Tyrosine for depression. *J Psychiatr Res* 1982-1983;17(2):175-80. (Review)
- Gibson C, Gelenberg A. Tyrosine for the treatment of depression. *Adv Biol Psychiatry* 1983;10:148-159.
- Goff DC. Two cases of hypomania following the addition of L-tryptophan to a monoamine oxidase inhibitor. *Am J Psychiatry* 1985;142(12):1487-1488.
- Gold MS, Verebey K. The psychopharmacology of cocaine. *Psychiatric Ann* 1984;14:714-723.
- Growdon JH, Melamed E, Logue M, et al. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. *Life Sci* 1982;30:827-832.
- Haavik J. L-DOPA is a substrate for tyrosine hydroxylase. *J Neurochem* 1997;69(4):1720-1728.
- Hull KM, Maher TJ. L-Tyrosine potentiates the anorexia induced by mixed-acting sympathomimetic drugs in hyperphagic rats. *J Pharmacol Exp Ther* 1990;255(2):403-409.
- Kelly GS. Nutritional and botanical interventions to assist with the adaptation to stress. *Altern Med Rev* 1999;4940:249-265. (Review)
- Koch R. Tyrosine supplementation for phenylketonuria treatment. *Am J Clin Nutr* 1996;64(6):974-975. (Comment, Editorial)
- Lehnert H, Wurtman RJ. Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. *Psychother Psychosom* 1993;60(1):18-32. (Review)

Citations and Reference Literature: Tyrosine

- Lemoine P, Robelin N, Sebert P, et al. L-tyrosine: a long term treatment of Parkinson's disease. *C R Acad Sci III* 1989;309:43-47.
- Lenke RR, Koch R, Fishler K, et al. Tyrosine supplementation during pregnancy in a woman with classical phenylketonuria: a case report. *J Reprod Med* 1983;28(6):411-414.
- Marz R. Medical nutrition from Marz. 2nd ed. Portland, OR: Omni Press; 1997.
- Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. *J Affect Disord* 1994;3291:37-44.
- Meyer JS, Welch KM, Deshmukh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease. *J Am Ger Soc* 1977;25(7):289-298.
- Meyers S. Use of neurotransmitter precursors for treatment of depression. *Altern Med Rev* 2000;5(1):64-71. (Review)
- Moir AT, Yates CM. Interaction in the cerebral metabolism of the biogenic amines: effect of phenelzine on this interaction. *Br J Pharmacol* 1972;45(2):265-274.
- Moller SE, Moller BM, Olesen M, et al. Effects of oral contraceptives on plasma neutral amino acids and cholesterol during a menstrual cycle. *Eur J Clin Pharmacol* 1996;50(3):179-184.
- Moller SE. Carbohydrate/protein selection in a single meal correlated with plasma tryptophan and tyrosine ratios to neutral amino acids in fasting individuals. *Physiol Behav* 1986;38(2):175-183.
- Moller SE. Tryptophan and tyrosine availability and oral contraceptives. *Lancet* 1979;2(8140):472.
- Moret J, Lemoine P, Sanchez P, et al. Treatment of narcolepsy with L-tyrosine. *Lancet* 1988;2(8626-8627):1458-1459.
- Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. *Aviat Space Environ Med* 1995;66(4):313-319.
- Parry BL. The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications. *CNS Drugs* 2001;15(4):277-285.
- Pizzorno JE, Murray MT. Textbook of natural medicine. Vol 2. New York: Churchill Livingstone; 1999:1049-1059.
- Ponto LB, Perry PJ, Liskow BI, et al. Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. *Am J Hosp Pharm* 1977;6:954-961.
- Poustie VJ, Rutherford P. Tyrosine supplementation for phenylketonuria. *Cochrane Database Syst Rev* 2000;(2):CD001507.
- Reimherr FW, Wender PH, Wood RD, et al. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. *Am J Psychiatry* 1987;144:1071-1073.
- Rohr FJ, Lobbregt D, Levy HL. Tyrosine supplementation in the treatment of maternal phenylketonuria. *Am J Clin Nutr* 1998;67(3):473-476.
- Rosecan JS, Nunes EV. Psychopharmacological management of cocaine abuse. In: Spitz HI, Rosecan JS, eds. Cocaine abuse: new directions in treatment and research. New York: Brunner/Mazel; 1987.
- Salter CA. Dietary tyrosine as an aid to stress resistance among troops. *Milit Med* 1989;154:144-146.
- Shurtleff D, Thomas JR, Schrot J, et al. Tyrosine reverses a cold-induced working memory deficit in humans. *Pharmacol Biochem Behav* 1994;47:935-941.
- Smith ML, Hanley WB, Clarke JT, et al. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. *Arch Dis Child* 1998;78(2):116-121.
- Tennant F, Berman, ML. Stepwise detoxification from cocaine: a promising regimen. *Postgrad Med* 1988;84:225-230,232,235.
- Threlkeld DS, ed. Central nervous system drugs, antidepressants, monoamine oxidase inhibitors. In: Facts and comparisons drug information. St Louis: Facts and Comparisons; 1997.
- van Spronsen FJ, van Rijn M, Bekhof J, et al. Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets. *Am J Clin Nutr* 2001;73(2):153-157.
- Wagenmakers AJ. Amino acid supplements to improve athletic performance. *Curr Opin Clin Nutr Metab Care* 1999;2(6):539-544.
- Werbach MR. Foundations of nutritional medicine. Tarzana, CA: Third Line Press; 1997. (Review)
- Wood DR, Reimherr FW, Wender PH. Amino acid precursors for the treatment of attention deficit disorder, residual type. *Psychopharmacol Bull* 1985;21(1):146-149.
- Yehuda S. Possible anti-Parkinson properties of N-(alpha-linolenoyl) tyrosine: a new molecule. *Pharmacol Biochem Behav* 2002;72(1-2):7-11.
- Young SN. Behavioral effects of dietary neurotransmitter precursors: basic and clinical aspects. *Neurosci Biobehav Rev* 1996;20:313-323.